Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1994 1
1995 1
1996 1
2005 1
2006 2
2007 1
2008 1
2010 2
2011 1
2014 2
2016 3
2017 1
2019 3
2020 1
2021 6
2022 8
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?
Juarez-Vignon Whaley JJ, Afkhami M, Onyshchenko M, Massarelli E, Sampath S, Amini A, Bell D, Villaflor VM. Juarez-Vignon Whaley JJ, et al. Curr Treat Options Oncol. 2023 Sep;24(9):1138-1166. doi: 10.1007/s11864-023-01101-3. Epub 2023 Jun 15. Curr Treat Options Oncol. 2023. PMID: 37318724 Free PMC article. Review.
Nasopharyngeal carcinoma (NPC) is distinct in its anatomic location and biology from other epithelial head and neck cancer (HNC). ...Hence, this remains the major challenge for treatment options. Nasopharyngeal carcinoma is challenging as it is really …
Nasopharyngeal carcinoma (NPC) is distinct in its anatomic location and biology from other epithelial head and neck cancer (HN …
Treatment for metastatic nasopharyngeal carcinoma.
Bensouda Y, Kaikani W, Ahbeddou N, Rahhali R, Jabri M, Mrabti H, Boussen H, Errihani H. Bensouda Y, et al. Eur Ann Otorhinolaryngol Head Neck Dis. 2011 Apr;128(2):79-85. doi: 10.1016/j.anorl.2010.10.003. Epub 2010 Dec 21. Eur Ann Otorhinolaryngol Head Neck Dis. 2011. PMID: 21177151 Free article. Review.
Nasopharyngeal carcinoma (NPC) is a specific entity different from head and neck carcinoma. ...The present study presents a review of the literature concerning the various studies of metastatic NPC....
Nasopharyngeal carcinoma (NPC) is a specific entity different from head and neck carcinoma. ...The present study presen …
Treatment strategy for de novo metastatic nasopharyngeal carcinoma: a literature review.
Liu Q, Li J, Ng WT, Lee AWM. Liu Q, et al. Chin Clin Oncol. 2023 Aug;12(4):43. doi: 10.21037/cco-23-32. Chin Clin Oncol. 2023. PMID: 37699604 Free article. Review.
BACKGROUND AND OBJECTIVE: Nasopharyngeal carcinoma (NPC) with de novo distant metastasis (M1) is classified as stage IVB in the 8th edition of the staging system jointly adopted by the American Joint Committee on Cancer and the International Union against Cancer Con …
BACKGROUND AND OBJECTIVE: Nasopharyngeal carcinoma (NPC) with de novo distant metastasis (M1) is classified as stage IVB in th …
Evaluation and management of neck masses in children.
Meier JD, Grimmer JF. Meier JD, et al. Am Fam Physician. 2014 Mar 1;89(5):353-8. Am Fam Physician. 2014. PMID: 24695506 Free article. Review.
Although rare in children, malignant lesions occurring in the neck include lymphoma, rhabdomyosarcoma, thyroid carcinoma, and metastatic nasopharyngeal carcinoma. Workup for a neck mass may include a complete blood count; purified protein derivative te …
Although rare in children, malignant lesions occurring in the neck include lymphoma, rhabdomyosarcoma, thyroid carcinoma, and meta …
Optimizing the treatment mode for de novo metastatic nasopharyngeal carcinoma with bone-only metastasis.
Lin C, Lin S, Zhu L, Lin S, Pan J, Xu Y. Lin C, et al. BMC Cancer. 2022 Jan 4;22(1):35. doi: 10.1186/s12885-021-09152-1. BMC Cancer. 2022. PMID: 34983459 Free PMC article.
BACKGROUND: No standard radiotherapy regimens have been established for the treatment of de novo metastatic nasopharyngeal carcinoma (mNPC) with bone-only metastasis. ...Multivariate analysis confirmed that fewer bone metastases ( 5) and more chemotherapy cyc …
BACKGROUND: No standard radiotherapy regimens have been established for the treatment of de novo metastatic nasopharyngeal …
Global longitudinal assessment of treatment outcomes in recurrent/metastatic nasopharyngeal carcinoma: GLANCE-NPC study.
Ahn MJ, Chirovsky D, Kuyas H, Auclair V, Abounit S, Joo S, Shah R, Yang MH. Ahn MJ, et al. Future Oncol. 2021 Jun;17(16):2015-2025. doi: 10.2217/fon-2020-1087. Epub 2021 Feb 19. Future Oncol. 2021. PMID: 33601910 Free article.
Aim: Given a lack of standard of care treatment for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), we assessed treatment patterns and overall survival in the real-world setting. ...Conclusion: Prognosis in R/M NPC with distant metastases rema …
Aim: Given a lack of standard of care treatment for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), we …
Treatment approaches to nasopharyngeal carcinoma: a review.
Caponigro F, Longo F, Ionna F, Perri F. Caponigro F, et al. Anticancer Drugs. 2010 Jun;21(5):471-7. doi: 10.1097/CAD.0b013e328337160e. Anticancer Drugs. 2010. PMID: 20124988 Review.
Early-stage nasopharyngeal carcinoma (T1-2a;N0;M0) represents a small proportion of nasopharyngeal tumors. ...Similarly, the role of neoadjuvant chemotherapy before concomitant chemoradiotherapy is a matter of interest. In patients with recurrent/metastati …
Early-stage nasopharyngeal carcinoma (T1-2a;N0;M0) represents a small proportion of nasopharyngeal tumors. ...Similarly …
Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients.
Jiang Y, Fang T, Lu N, Bei W, Dong S, Xia W, Liang H, Xiang Y. Jiang Y, et al. Crit Rev Oncol Hematol. 2023 Oct;190:104113. doi: 10.1016/j.critrevonc.2023.104113. Epub 2023 Aug 24. Crit Rev Oncol Hematol. 2023. PMID: 37633346 Free article. Review.
We aim to evaluate the efficacy and safety of anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) patients who progressed to previous anti-PD1 therapy. ...Among th …
We aim to evaluate the efficacy and safety of anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment in recurrent …
A Pilot Study of Anlotinib as a Combination Treatment in Advanced Nasopharyngeal Carcinoma.
Zhou R, Zhou P, Yu YF, Lin Q, Wu SG. Zhou R, et al. Curr Cancer Drug Targets. 2024;24(3):319-327. doi: 10.2174/1568009623666230810121918. Curr Cancer Drug Targets. 2024. PMID: 37563818
AIMS: To investigate the short-term objective response and treatment toxicity of anlotinib as a combination treatment in patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (RM-NPC). METHODS: Patients with RM-NPC who received anlotinib as a combina …
AIMS: To investigate the short-term objective response and treatment toxicity of anlotinib as a combination treatment in patients with Recur …
Local treatment of metastases plus systemic chemotherapy on overall survival of patients with metastatic nasopharyngeal carcinoma.
Liao W, He J, Gou Q, Duan B, Ai P, Liu L, Li Y, Ren K, Yao M, Chen N. Liao W, et al. Head Neck. 2021 Aug;43(8):2423-2433. doi: 10.1002/hed.26706. Epub 2021 May 3. Head Neck. 2021. PMID: 33939262 Free PMC article.
BACKGROUND: To investigate the effect of local treatment of metastases on overall survival (OS) of patients with metastatic nasopharyngeal carcinoma (NPC). METHODS: One hundred and forty-seven patients were included. ...The survival benefit of local treatment …
BACKGROUND: To investigate the effect of local treatment of metastases on overall survival (OS) of patients with metastatic nasoph …
42 results